AR112683A1 - Forma cristalina de base libre de levodopa, su sal de adición y composición farmaceutica que la comprende - Google Patents
Forma cristalina de base libre de levodopa, su sal de adición y composición farmaceutica que la comprendeInfo
- Publication number
- AR112683A1 AR112683A1 ARP180102329A AR112683A1 AR 112683 A1 AR112683 A1 AR 112683A1 AR P180102329 A ARP180102329 A AR P180102329A AR 112683 A1 AR112683 A1 AR 112683A1
- Authority
- AR
- Argentina
- Prior art keywords
- levodopa
- around
- pharmaceutical composition
- addition salt
- crystal form
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
- C07C237/20—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton containing six-membered aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Abstract
Una base libre de amida de levodopa cristalina y un proceso para elaborarla. En particular, una base libre de amida de levodopa cristalina sustancialmente pura, adecuada para la preparación de composiciones farmacéuticas para el tratamiento de enfermedades o trastornos caracterizados por la neurodegeneración y/o niveles reducidos de dopamina cerebral, tales como la enfermedad de Parkinson. Reivindicación 1: Una forma cristalina de base libre de L-dopamida, en donde la forma cristalina se caracteriza por un patrón de difracción de rayos X de polvo que tiene picos característicos en grados 2q a alrededor de 19,7 y alrededor de 21,0. Reivindicación 2: La forma cristalina de acuerdo con la reivindicación 1 también puede tener picos característicos en grados 2q a alrededor de 18,1 y alrededor de 28,9.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762548111P | 2017-08-21 | 2017-08-21 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR112683A1 true AR112683A1 (es) | 2019-11-27 |
Family
ID=63683238
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP180102329 AR112683A1 (es) | 2017-08-21 | 2018-08-15 | Forma cristalina de base libre de levodopa, su sal de adición y composición farmaceutica que la comprende |
Country Status (2)
Country | Link |
---|---|
AR (1) | AR112683A1 (es) |
WO (1) | WO2019038639A1 (es) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2967693T3 (es) | 2014-03-13 | 2024-05-03 | Neuroderm Ltd | Composiciones del inhibidor de la dopa descarboxilasa |
US10258585B2 (en) | 2014-03-13 | 2019-04-16 | Neuroderm, Ltd. | DOPA decarboxylase inhibitor compositions |
US11213502B1 (en) | 2020-11-17 | 2022-01-04 | Neuroderm, Ltd. | Method for treatment of parkinson's disease |
US11331293B1 (en) | 2020-11-17 | 2022-05-17 | Neuroderm, Ltd. | Method for treatment of Parkinson's disease |
US11844754B2 (en) | 2020-11-17 | 2023-12-19 | Neuroderm, Ltd. | Methods for treatment of Parkinson's disease |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004069146A2 (en) | 2003-02-07 | 2004-08-19 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | L-dopa amide derivatives and uses thereof |
CN108495617A (zh) | 2015-11-24 | 2018-09-04 | 纽罗德姆有限公司 | 包含左旋多巴酰胺的药物组合物和其用途 |
-
2018
- 2018-08-15 WO PCT/IB2018/056127 patent/WO2019038639A1/en active Application Filing
- 2018-08-15 AR ARP180102329 patent/AR112683A1/es unknown
Also Published As
Publication number | Publication date |
---|---|
WO2019038639A1 (en) | 2019-02-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR112683A1 (es) | Forma cristalina de base libre de levodopa, su sal de adición y composición farmaceutica que la comprende | |
PH12019502793A1 (en) | Aadc polynucleotides for the treatment of parkinson`s disease | |
CL2019001066A1 (es) | Sal de (s)-csa de s-ketamina, sal de (r)-csa de s-ketamina y procesos para la preparación de s-ketamina (divisional solicitud 201702854) | |
UA113165C2 (xx) | Застосування комбінації баклофену і акампросату для лікування неврологічних захворювань та композиція, яка містить баклофен і акампросат | |
MX2018000929A (es) | Derivados de 1,1,1-trifluoro-3-hidroxipropan-2-il carbamato y derivados de 1,1,1-trifluoro-4- hidroxibutan-2-il carbamato como inhibidores de magl. | |
ECSP18078877A (es) | Moduladores alostéricos de receptores de acetilcolina nicotínicos | |
NZ703341A (en) | Compositions comprising apomorphine and organic acids and uses thereof | |
WO2018060732A3 (en) | Compositions and methods for treating seizure disorders | |
MX2022016276A (es) | Nuevos profarmacos de catecolamina para uso en el tratamiento de la enfermedad de parkinson. | |
MX367618B (es) | Compuestos de benzofuranilo y benzoxazolilo sustituídos, y sus usos. | |
WO2017090039A3 (en) | Pharmaceutical compositions comprising levodopa amide and uses thereof | |
AR112472A1 (es) | Forma de sales cristalinas de amida de levodopa y métodos para elaborarlas y usarlas | |
MX2016005668A (es) | Formas cristalinas de compuestos terapeuticos y sus usos. | |
MY189740A (en) | Butylphthalide-telmisartan heterocomplex, preparation method and application thereof | |
CA2864606C (en) | Methods of treating and preventing diseases and disorders of the central nervous system | |
EA201290856A1 (ru) | Стабилизированная фармацевтическая композиция | |
AU2015375259A8 (en) | Trifluoroacetyl hydrazide compounds and methods of preparation and uses thereof | |
PE20210157A1 (es) | Polimorfos y formas solidas de un compuesto de pirimidinilamino-pirazol y metodos de produccion | |
ZA202101489B (en) | Compositions and methods for the treatment of parkinson's disease | |
CO2019007670A2 (es) | Un derivado de oxazina base libre en forma cristalina | |
MX2010008706A (es) | Derivados de fenil-prenilo, de origen marino y sintetico. para el tratamiento de enfermedades o trastornos cognitivos, neurodegenerativos o neuronales. | |
AU2018331371C1 (en) | A novel small molecule compound | |
PH12019502792A1 (en) | Tetrahydropyridopyrazine modulators of gpr6 | |
EP3085691A4 (en) | Method for preparing the anhydrous crystalline form of isoniazid-derived hydrazone, thus produced crystalline polymorph of the anhydrous form, use thereof for the treatment of alzheimer's disease, parkinsonism and other neurodegenerative disorders, and pharmaceutical composition | |
MX2016015767A (es) | Compuestos para el tratamiento de convulsiones y otros trastornos y condiciones del sistema nervioso central. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |